IBI3032 / Innovent Biologics - LARVOL DELTA

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study of IBI3032 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Fortvita Biologics (USA)Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of IBI3032 in Chinese Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=92 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial • Genetic Disorders • Obesity

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) | Not yet recruiting ➔ Recruiting

Enrollment open

A Study of IBI3032 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Fortvita Biologics (USA)Inc.

New P1 trial

A Study of IBI3032 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center)

New P1 trial

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 (PRNewswire) - "Innovent Biologics...announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist....The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025."

IND • New P1 trial • Obesity